ABSTRACT
ABSTRACT: In physiological conditions, few circulating hematopoietic stem/progenitor cells (cHSPCs) are present in the peripheral blood, but their contribution to human hematopoiesis remain unsolved. By integrating advanced immunophenotyping, single-cell transcriptional and functional profiling, and integration site (IS) clonal tracking, we unveiled the biological properties and the transcriptional features of human cHSPC subpopulations in relationship to their bone marrow (BM) counterpart. We found that cHSPCs reduced in cell count over aging and are enriched for primitive, lymphoid, and erythroid subpopulations, showing preactivated transcriptional and functional state. Moreover, cHSPCs have low expression of multiple BM-retention molecules but maintain their homing potential after xenotransplantation. By generating a comprehensive human organ-resident HSPC data set based on single-cell RNA sequencing data, we detected organ-specific seeding properties of the distinct trafficking HSPC subpopulations. Notably, circulating multi-lymphoid progenitors are primed for seeding the thymus and actively contribute to T-cell production. Human clonal tracking data from patients receiving gene therapy (GT) also showed that cHSPCs connect distant BM niches and participate in steady-state hematopoietic production, with primitive cHSPCs having the highest recirculation capability to travel in and out of the BM. Finally, in case of hematopoietic impairment, cHSPCs composition reflects the BM-HSPC content and might represent a biomarker of the BM state for clinical and research purposes. Overall, our comprehensive work unveiled fundamental insights into the in vivo dynamics of human HSPC trafficking and its role in sustaining hematopoietic homeostasis. GT patients' clinical trials were registered at ClinicalTrials.gov (NCT01515462 and NCT03837483) and EudraCT (2009-017346-32 and 2018-003842-18).
Subject(s)
Hematopoiesis , Hematopoietic Stem Cells , Homeostasis , Animals , Humans , Mice , Hematopoietic Stem Cells/cytology , Hematopoietic Stem Cells/metabolism , Single-Cell AnalysisABSTRACT
Dysregulation of the interleukin-1 (IL-1) pathway leads to immune diseases that can result in chronic tissue and organ inflammation. Although IL-1 blockade has shown promise in ameliorating these symptoms and improving patients' quality of life, there is an urgent need for more effective, long-lasting treatments. We developed a lentivirus (LV)-mediated gene transfer strategy using transplanted autologous hematopoietic stem/progenitor cells (HSPCs) as a source of IL-1 receptor antagonist (IL-1RA) for systemic delivery to tissues and organs. Transplantation of mouse and human HSPCs transduced with an IL-1RA-encoding LV ensured stable IL-1RA production while maintaining the clonogenic and differentiation capacities of HSPCs in vivo. We examined the efficacy of cell-mediated IL-1RA delivery in three models of IL-1-dependent inflammation, for which treatment hindered neutrophil recruitment in an inducible model of gout, prevented systemic and multi-tissue inflammation in a genetic model of cryopyrin-associated periodic syndromes, and reduced disease severity in an experimental autoimmune encephalomyelitis model of multiple sclerosis. Our findings demonstrate HSPC-mediated IL-1RA delivery as a potential therapeutic modality that can be exploited to suppress tissue and organ inflammation in diverse immune-related diseases involving IL-1-driven inflammation.
Subject(s)
Encephalomyelitis, Autoimmune, Experimental , Interleukin 1 Receptor Antagonist Protein , Animals , Humans , Encephalomyelitis, Autoimmune, Experimental/therapy , Inflammation/therapy , Interleukin-1 , Lentivirus , Quality of Life , MiceABSTRACT
Mobilized peripheral blood is increasingly used instead of bone marrow as a source of autologous hematopoietic stem/progenitor cells for ex vivo gene therapy. Here, we present an unplanned exploratory analysis evaluating the hematopoietic reconstitution kinetics, engraftment and clonality in 13 pediatric Wiskott-Aldrich syndrome patients treated with autologous lentiviral-vector transduced hematopoietic stem/progenitor cells derived from mobilized peripheral blood (n = 7), bone marrow (n = 5) or the combination of the two sources (n = 1). 8 out of 13 gene therapy patients were enrolled in an open-label, non-randomized, phase 1/2 clinical study (NCT01515462) and the remaining 5 patients were treated under expanded access programs. Although mobilized peripheral blood- and bone marrow- hematopoietic stem/progenitor cells display similar capability of being gene-corrected, maintaining the engineered grafts up to 3 years after gene therapy, mobilized peripheral blood-gene therapy group shows faster neutrophil and platelet recovery, higher number of engrafted clones and increased gene correction in the myeloid lineage which correlate with higher amount of primitive and myeloid progenitors contained in hematopoietic stem/progenitor cells derived from mobilized peripheral blood. In vitro differentiation and transplantation studies in mice confirm that primitive hematopoietic stem/progenitor cells from both sources have comparable engraftment and multilineage differentiation potential. Altogether, our analyses reveal that the differential behavior after gene therapy of hematopoietic stem/progenitor cells derived from either bone marrow or mobilized peripheral blood is mainly due to the distinct cell composition rather than functional differences of the infused cell products, providing new frames of references for clinical interpretation of hematopoietic stem/progenitor cell transplantation outcome.
Subject(s)
Hematopoietic Stem Cell Transplantation , Wiskott-Aldrich Syndrome , Humans , Child , Animals , Mice , Bone Marrow , Hematopoietic Stem Cells , Genetic Therapy , Wiskott-Aldrich Syndrome/genetics , Granulocyte Colony-Stimulating FactorABSTRACT
Mesenchymal stromal cells (MSCs) have been employed in vitro to support hematopoietic stem and progenitor cell (HSPC) expansion and in vivo to promote HSPC engraftment. Based on these studies, we developed an MSC-based co-culture system to optimize the transplantation outcome of clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 gene-edited (GE) human HSPCs. We show that bone marrow (BM)-MSCs produce several hematopoietic supportive and anti-inflammatory factors capable of alleviating the proliferation arrest and mitigating the apoptotic and inflammatory programs activated in GE-HSPCs, improving their expansion and clonogenic potential in vitro. The use of BM-MSCs resulted in superior human engraftment and increased clonal output of GE-HSPCs contributing to the early phase of hematological reconstitution in the peripheral blood of transplanted mice. In conclusion, our work poses the biological bases for a novel clinical use of BM-MSCs to promote engraftment of GE-HSPCs and improve their transplantation outcome.
Subject(s)
Hematopoietic Stem Cell Transplantation , Mesenchymal Stem Cells , Humans , Animals , Mice , Gene Editing , CRISPR-Cas Systems , Hematopoietic Stem Cells , Hematopoietic Stem Cell Transplantation/methodsABSTRACT
Chronic granulomatous disease (CGD) is a rare inherited disorder due to loss-of-function mutations in genes encoding the NADPH oxidase subunits. Hematopoietic stem and progenitor cell (HSPC) gene therapy (GT) using regulated lentiviral vectors (LVs) has emerged as a promising therapeutic option for CGD patients. We performed non-clinical Good Laboratory Practice (GLP) and laboratory-grade studies to assess the safety and genotoxicity of LV targeting myeloid-specific Gp91phox expression in X-linked chronic granulomatous disease (XCGD) mice. We found persistence of gene-corrected cells for up to 1 year, restoration of Gp91phox expression and NADPH oxidase activity in XCGD phagocytes, and reduced tissue inflammation after LV-mediated HSPC GT. Although most of the mice showed no hematological or biochemical toxicity, a small subset of XCGD GT mice developed T cell lymphoblastic lymphoma (2.94%) and myeloid leukemia (5.88%). No hematological malignancies were identified in C57BL/6 mice transplanted with transduced XCGD HSPCs. Integration pattern analysis revealed an oligoclonal composition with rare dominant clones harboring vector insertions near oncogenes in mice with tumors. Collectively, our data support the long-term efficacy of LV-mediated HSPC GT in XCGD mice and provide a safety warning because the chronic inflammatory XCGD background may contribute to oncogenesis.
Subject(s)
Genetic Therapy , Genetic Vectors/genetics , Granulomatous Disease, Chronic/complications , Granulomatous Disease, Chronic/therapy , Hematologic Neoplasms/etiology , Lentivirus/genetics , Animals , Disease Models, Animal , Genetic Therapy/adverse effects , Genetic Therapy/methods , Genetic Vectors/administration & dosage , Granulomatous Disease, Chronic/genetics , Humans , Mice , NADPH Oxidase 2/genetics , NADPH Oxidase 2/metabolism , Time Factors , Treatment OutcomeABSTRACT
Chronic granulomatous disease (CGD) is a primary immunodeficiency due to a deficiency in one of the subunits of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex. CGD patients are characterized by an increased susceptibility to bacterial and fungal infections, and to granuloma formation due to the excessive inflammatory responses. Several gene therapy approaches with lentiviral vectors have been proposed but there is a lack of in vivo data on the ability to control infections and inflammation. We set up a mouse model of acute infection that closely mimic the airway infection in CGD patients. It involved an intratracheal injection of a methicillin-sensitive reference strain of S. aureus. Gene therapy, with hematopoietic stem cells transduced with regulated lentiviral vectors, restored the functional activity of NADPH oxidase complex (with 20-98% of dihydrorhodamine positive granulocytes and monocytes) and saved mice from death caused by S. aureus, significantly reducing the bacterial load and lung damage, similarly to WT mice even at low vector copy number. When challenged, gene therapy-treated XCGD mice showed correction of proinflammatory cytokines and chemokine imbalance at levels that were comparable to WT. Examined together, our results support the clinical development of gene therapy protocols using lentiviral vectors for the protection against infections and inflammation.
Subject(s)
Genetic Therapy/methods , Granulomatous Disease, Chronic/complications , Hematopoietic Stem Cell Transplantation/methods , Membrane Glycoproteins/genetics , NADPH Oxidases/genetics , Pneumonia, Staphylococcal/therapy , Staphylococcus aureus/physiology , Animals , Bacterial Load , Cells, Cultured , Chemokines/metabolism , Cytokines/metabolism , Disease Models, Animal , Genetic Vectors/administration & dosage , Granulomatous Disease, Chronic/genetics , Hematopoietic Stem Cells/virology , Humans , Lentivirus/genetics , Mice , NADPH Oxidase 2 , Pneumonia, Staphylococcal/genetics , Pneumonia, Staphylococcal/microbiologyABSTRACT
Con el objetivo de profundizar en la patogenia de enfermedades que involucren al sistema nervioso central, un colectivo de los laboratorios se dio a la tarea de detectar autoanticuerpos antineuronas en pacientes con estas enfermedades mediante la técnica de inmunofluorescencia indirecta. Se analizaron 31 sueros de pacientes y 72 controles, se obtuvo como resultado una sensibilidad de 77(por ciento) y una especificidad de 95(por ciento) en la técnica realizada, el valor predictivo positivo fue de 88(por ciento) y el valor predictivo negativo de 89(por ciento). Esto sugiere que en estas enfermedades existe una pérdida de equilibrio de los mecanismos que en el cerebro evitan la iniciación de respuesta inmune a ese nivel(AU)
Subject(s)
Humans , Male , Female , Fluorescent Antibody Technique, Indirect , Central Nervous System Diseases/immunology , AutoantibodiesABSTRACT
Con el descubrimiento de la técnica de microlinfocitotoxicidad para la detección de los antígenos del sistema mayor de histocompatibilidad, se impulsó notablemente la producción de reactivos para esta finalidad por constituir la base de las técnicas de tipificación serológicas. En 1990 el laboratorio comienza a asumir la producción de estos diagnosticadores y obtiene el primer lote de antisueros HLA clase I, producidos a partir de suero retroplacentario humano. Después, con la adquisición de la tecnología Patimed-Leica, la producción se diversifica y cuenta en la actualidad con 124 antisueros con un coeficiente de correlación mayor que 0,700 para 64 especificidades HLA diferentes, que han sido validados en laboratorios internacionales de referencia. Otras producciones son los sueros de conejo como fuente de complemento estándar y de baja toxicidad, una formulación de placa seca para la detección del antígeno B27, así como varias formulaciones de baterías de tipaje HLA Clase I(AU)
Subject(s)
Histocompatibility Antigens , Indicators and Reagents , Immune SeraABSTRACT
Con el descubrimiento de la técnica de microlinfocitotoxicidad para la detección de los antígenos del sistema mayor de histocompatibilidad, se impulsó notablemente la producción de reactivos para esta finalidad por constituir la base de las técnicas de tipificación serológicas. En 1990 el laboratorio comienza a asumir la producción de estos diagnosticadores y obtiene el primer lote de antisueros HLA clase I, producidos a partir de suero retroplacentario humano. Después, con la adquisición de la tecnología Patimed-Leica, la producción se diversifica y cuenta en la actualidad con 124 antisueros con un coeficiente de correlación mayor que 0,700 para 64 especificidades HLA diferentes, que han sido validados en laboratorios internacionales de referencia. Otras producciones son los sueros de conejo como fuente de complemento estándar y de baja toxicidad, una formulación de placa seca para la detección del antígeno B27, así como varias formulaciones de baterías de tipaje HLA Clase I(AU)